Health Canada has announced that Apotex is recalling 2 lots of its mometasone nasal spray, a generic of Nasonex, due to possible contamination with Burkholderia cepacia complex. Lot TX5343 has an expiration date of September 2025, and lot TZ2586 has an expiration date in October 2025.
APO-Mometasone nasal spray is approved in Canada for the treatment of allergies in children as young as 3; for the treatment of sinusitis in ages 12 and over; and for the treatment of nasal polyps in adults. According to Health Canada, B. cepacia complex is primarily a threat to children, patients with chronic lung disease, and people with weakened immune systems.
Read the Health Canada press release.
